{"entity":{"id":"nct06092242","kind":"trial","name":"The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of trifluridine/tipiracil and bevacizumab (glioblastoma use) in colorectal cancer, run by The Second Affiliated Hospital of Shandong First Medical University, not yet recruiting.","summary":"The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT06092242 by The Second Affiliated Hospital of Shandong First Medical University, with a registry enrolment figure of 50 participants, started 2023-10-15 and due to reach its primary completion in 2025-10-15. Interventions recorded: Tas-102(Suyuan) combined with bevacizumab. Conditions listed: Colorectal Cancer. Primary outcome: Progression Free Survival. Colorectal eligibility wording from the registry: \"Definitive histological or cytological evidence of adenocarcinoma of the colon or rectum;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06092242","url":"https://clinicaltrials.gov/study/NCT06092242"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["trifluridine-tipiracil","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06092242","phase":"2","setting":"The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer","sponsor":"The Second Affiliated Hospital of Shandong First Medical University","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06092242/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}